投资快报 3

葉芬

回复 2020# imaboy


    EDAP 有看沒有買。

roberto

最近药股都冲到很凶, 恭喜各位啦!

migo

回复 2021# 葉芬
芬姐。Arna 會很快就上4.00的哦

roberto

Analysts Say AEterna Zentaris Should Be Valued 200% to 300% Higher
I am shocked AEterna Zentaris (AEZS) hasn't already risen above $2 a share given the fact AEZS has had 3 analyst give investors very bullish views over the past 2 1/2 weeks. AEZS has provided investors with exceptional details that have clearly not been reflected in the stock price.
This week Versant analyst raised his price target on AEZS:

* DECEMBER 15, 2010, 12:36 P.M. ET
AEterna Zentaris Target Raised To $4 From $2.50 By Versant Partners analyst Douglas W. Loe
Last week Dundee AEZS analyst raised his price target:

* DECEMBER 6, 2010, 8:45 A.M. ET
AEterna Zentaris Target Raised To $3 From $2 By Dundee.
AEZS had new analyst coverage with a BUY from MLV:

* NOVEMBER 29, 2010, 11:54 A.M. ET
McNicoll Lewis & Vlak Starts AEterna Zentaris at Buy Price Target $5.50; Sales Revenue and Funded Phase III Trials Support Perifosine Development.
McNicoll Lewis & Vlak Analyst George B. Zavoico

AEZS presented a Comprehensive R&D review and its strategic outlook for 2011, at the InterContinental New York Barclay Hotel in New York City on Dec 14, 2010, Details below:
Key Announcements
* Perifosine   
o On track for completion of the Phase 3 X-PECT trial in metastatic colorectal cancer expected in the second half of 2011;
o Additional centers opened outside the U.S. for ongoing Phase 3 trial in multiple myeloma - patients under screening;
o Decision to come on the development in new indications such as Chronic Lymphocytic Leukemia (CLL).
* AEZS-108
o First pivotal study in endometrial cancer to be initiated;
o Phase 1/2 trial initiated in castration refractory prostate cancer at Norris Comprehensive Cancer Center - first patients treated;
o Phase 1/2 trial initiated in refractory bladder cancer at Sylvester Comprehensive Cancer Center - patients under screening;
o Further proof-of-concept studies to be initiated in pancreatic and breast cancer.
* AEZS-130 (Solorel&#174
o NDA to be filed as an oral diagnostic test for growth hormone deficiency (GHD) in adults;
o Trial to be initiated as an oral diagnostic test for GHD in children;
o Proof-of-concept study to be initiated in cancer induced cachexia.
* AEZS-112, AEZS-120 and PI3K/Erk inhibitors
o Preclinical and early-stage clinical development to be pursued in oncology.
Review of ongoing late-stage clinical programs by distinguished Key Opinion Leaders
* Perifosine
o Phase 3 registration trial in metastatic colorectal cancer presented by Johanna Bendell, S.B., M.D., Director, GI Cancer Research - Associate Director, Drug Development Unit, Sarah Cannon Research Institute, Nashville;
o Phase 3 registration trial in multiple myeloma presented by Paul G. Richardson, M.D., Clinical Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Associate Professor of Medicine, Harvard Medical School, Boston.
* AEZS-108
o Phase 2 program in advanced endometrial and advanced ovarian cancer presented by David S. Miller, M.D., F.A.C.O.G., F.A.C.S., Director of Gynecologic Oncology, Dallas Foundation chair in Gynecologic Oncology, Professor of Obstetrics & Gynecology, University of Texas Southwestern Medical Center, Dallas.
* Solorel®:
o Phase 3 program as an oral diagnostic test for adult GHD presented by Beverly M.K. Biller, M.D., F.A.C.P., Professor of Medicine, Harvard Medical School, Faculty member - Neuroendocrine Unit, Massachusetts General Hospital, Boston.

2011 should be an exciting year for the Company as we will continue the late-stage development of our lead novel compounds," stated Juergen Engel, Ph.D., President and CEO at Aeterna Zentaris. "We look forward to the disclosure of Phase 3 results for perifosine in metastatic colorectal cancer, the initiation of a first pivotal trial in endometrial cancer with AEZS-108, as well as the completion of the Phase 3 trial with Solorel® in adult GHD and the NDA filing for the use as an oral diasnostic test in this indication. We will continue the preclinical and early clinical development of AEZS-112, AEZS-120 and PI3K/Erk inhibitors which could represent the way of the future in targeted cancer treatment. We feel confident that with the human and financial resources at hand, we will achieve our goals in the upcoming year for the benefit of both patients and shareholders.

A replay of the meeting is available on the Company's website in the "Newsroom" section under "Events and Webcasts" here.
I believe AEZS is ridiculously undervalued at $1.63 a share with a marketcap of just $135M. AEZS Perifosine partner Keryx Biopharma (KERX) has a marketcap of $295M with a stock price of $4.83. KERX stock price recently sold off from the $5 level in part due to the CEO Ron Bentsur selling 50,000 shares at $5.01 a share. I have spoken with Ron before who fully believes in Perifosine. I assume the only reason he sold some shares was to raise general money. I would not be suprised next year to see AEZS get a buy out offer. AEZS prospects are extremely compelling. I have added to my AEZS long position and will continue to buy. Read my prior AEZS articles for more details. Simple fact is AEZS should already be trading in the $3 range.

Disclosure: I am long AEZS, KERX.                           
About the author:     Jeremy Richards  
Jeremy Richards is the Manager/Director of Private Wealth Fund. He has twenty years investment expertise.

roberto

News releases

December 20, 2010

Aeterna Zentaris Receives Agreement from FDA on Special Protocol Assessment for Solorel® (AEZS-130, Macimorelin) to Complete Registration Study for Diagnosis of Adult Growth Hormone Deficiency Québec City, Canada, December 20, 2010 - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that it has reached agreement with the Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for Solorel® (AEZS-130, macimorelin) which will enable the Company to complete the ongoing registration study required to gain approval as a diagnostic test for Adult Growth Hormone Deficiency (AGHD).
"We are pleased with the agreement with the FDA and now look forward to the completion of the Phase 3 trial with Solorel® and the NDA filing in 2011 for use as a diagnostic test in AGHD", stated Juergen Engel, Ph.D., President and CEO at Aeterna Zentaris. "In line with our innovative approach, Solorel® could become the first approved oral test for the diagnosis of AGHD, providing patients with a potentially safer, accurate and more convenient alternative to the current injectable tests."
The study was initiated to compare the performance of Solorel® against the then-available diagnostic growth hormone releasing hormone (GHRH) Geref Diagnostic® + Arginine (ARG) standard test. GHRH Geref Diagnostic® was subsequently withdrawn from the market, worldwide, in 2008. At the time of withdrawal, the trial included 42 patients with AGHD and ten control subjects. In 2009, Aeterna Zentaris regained the rights to Solorel® and had been working with the FDA to establish the best way forward to complete this registration study and continue to utilize the data obtained thus far, in light of the loss of the original comparator.

Study Design

The protocol is titled,"A Multi-Center Study Investigating a New, Oral Growth Hormone Secretagogue (AEZS-130, formerly ARD-07) as a Growth Hormone (GH) Stimulation Test in Terms of Safety and Efficacy." (Clinicaltrials.gov Identifier: NCT00448747)
The SPA agreement has resulted in a modification of the original study, but does not alter the basic study design so that the completed portion of the study will work with the new part of the study to provide one, complete, Phase 3 study.

Original Study

The completed part of the study was a two-way crossover study, and included 42 patients with confirmed AGHD or multiple pituitary hormone deficiencies and a low insulin-like growth factor-I. A control group of 10 subjects without AGHD were matched to patients for age, gender, body mass index and (for females) estrogen status.

Each patient received two dosing regimens in random order, while fasting, at least 1 week apart. One regimen consisted of a 1 µg/kg (max. 100 µg) dose of GHRH (Geref Diagnostic®, Serono) with 30 g of ARG (Ar-Gine®, Pfizer) administered intravenously over 30 minutes; the other regimen was a dose of 0.5 mg/kg body weight of Solorel® given in an oral solution of 0.5 mg/ml.

SPA Agreed Study Amendment

Completion of the study will be accomplished with the following revisions/additions to the current protocol:

• An additional 30 normal controls subjects will be enrolled to match the AGHD patients from the original cohort;
• Further, an additional 20 subjects will be enrolled - 10 AGHD patients and 10 matched normal control subjects;
• The above will bring the database to approximately 100 patients;
• All subjects will be receiving a dose of 0.5 mg/kg body weight of Solorel®;
• As a secondary endpoint, the protocol will require that at least 8 of the 10 newly enrolled AGHD patients be correctly classified by a pre-specified peak Growth Hormone (GH) threshold level.

About Solorel®

Solorel®, a ghrelin agonist, is a novel orally active small molecule that stimulates the secretion of growth hormone (GH).The orally-administered product is currently in a Phase 3 trial for use as a simple diagnostic test for adult growth hormone deficiency (AGHD). Solorel® works by stimulating a patient’s GH secretion after which a healthcare provider will measure how well the body responds to that stimulation based on the patient’s GH levels over a period of time. Low GH levels, despite giving an effective stimulating agent, confirm a diagnosis of AGHD. Solorel® has been granted orphan-drug designation by the FDA for use as a diagnostic test for growth hormone deficiency. Aeterna Zentaris owns the worldwide rights to Solorel® which, if approved, would become the first orally available diagnostic test for AGHD.

About AGHD

AGHD affects 35,000 adult Americans, with 6,000 new adult patients diagnosed each year. Growth hormone (GH) not only plays an important role in growth from childhood to adulthood, but helps promote good health throughout life. AGHD is usually characterized by low energy levels, decreased strength and exercise tolerance, increased weight or difficulty losing weight, emotional changes, anxiety and impaired sleep. Available diagnostic tests for AGHD are complex and can produce significant side effects.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, ovarian, endometrial cancer and multiple myeloma. The Company’s innovative approach of "personalized medicine" means tailoring treatments to a patient’s specific condition and to unmet medical needs. Aeterna Zentaris’ deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.

Investor Relations
Ginette Vallières
Investor Relations Coordinator
(418) 652-8525 ext. 265
gvallieres@aezsinc.com

Media Relations
Paul Burroughs
Director of Communications
(418) 652-8525 ext. 406
pburroughs@aezsinc.com

葉芬

回复  葉芬
芬姐。Arna 會很快就上4.00的哦
migo 发表于 21-12-2010 09:37 AM

ARNA 昨晚也是有看沒有買。
看的時候是1.80，1.81...

昨晚 ARIA 也是起得不錯。


P/s: 呵呵 不能一次注意這樣多股。。

migo

回复 2026# 葉芬


    那位叫SUNNY仔的怎么没出现!他的ANX开始跑了!

葉芬

回复  葉芬


    那位叫SUNNY仔的怎么没出现!他的ANX开始跑了!
migo 发表于 21-12-2010 11:07 AM

Sunny小弟，他呀忙到每天數鈔票，沒空看股市。

migo

回复 2028# 葉芬


    你这几天数完了吗!

葉芬

回复  葉芬


    你这几天数完了吗!
migo 发表于 21-12-2010 11:14 AM

那夠你的梗，我的5分鐘就數完啦

葉芬

回复  葉芬


   最近都在忙些自己的生意,比较少做买卖了。目前手上只有MPEL, LVS 和 ctic. 昨天adbe 跌了20%。 近了600UNITS. ...
victan 发表于 23-9-2010 10:20 PM

Vic小弟，恭喜。。
昨晚 After Hours ADBE 上了 5% 。
因為她的Q4 2010業績很好。
今晚有好戲看了。

终景

mgm太早放了， 刚买了5800 shares YGE

葉芬

mgm太早放了， 刚买了5800 shares YGE
终景 发表于 21-12-2010 02:32 PM

有賺就好。

victan

回复 2031# 葉芬


    謝謝.    
   pre-market的价钱不如想象中的理想  
   守了2个多月，10多%的赚幅。。。

葉芬

回复  葉芬


    謝謝.   
   pre-market的价钱不如想象中的理想   
   守了2个多月 ...
victan 发表于 21-12-2010 06:31 PM

今晚Adobe起了5-6%，還不錯。
有賺就好。

葉芬

回复  migo


    HDY连续两天上超过10%,差别只是第一天在收市时套利持平,第二天侧一鼓作气劲扬14%,接近 ...
SUNNY仔 发表于 18-12-2010 11:41 PM

Sunny小弟，今晚輪到你的ANX大漲。。。
從高峰 3.20，現在是2.93， 希望你賣的Order有做到。

终景

有賺就好。
葉芬 发表于 21-12-2010 04:17 PM

走宝了，mgm 和 pcx 都在涨。

葉芬

走宝了，mgm 和 pcx 都在涨。
终景 发表于 22-12-2010 12:51 AM

這週末至下星期假期多，市場會比較靜，所以投機有賺記住要套利哦。。。

SUNNY仔

回复 2036# 葉芬


    芬姐,没跑到啦...今晚去朋友哪坐夜...回来看时已回落至$2.95了....再等咯...

葉芬

回复  葉芬


    芬姐,没跑到啦...今晚去朋友哪坐夜...回来看时已回落至$2.95了....再等咯...
SUNNY仔 发表于 22-12-2010 01:41 AM

預祝你的ANX今晚的股價更上一層樓。


昨晚的 FTK，SHZ，HDY，PZG，KOG 全部都有動作。

PZG After Hours 起了 6% 。。。


++++++++++++++++++++++


哦 忘了說 祝大家 “冬至節快樂” ！